{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451225761
| IUPAC_name = 5-(2-Ethoxy-5-<nowiki/>{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}phenyl)-1-methyl-3-propyl-1,4-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
| image = Lodenafil.svg
| width = 250

<!--Clinical data-->
| tradename = Helleva
| pregnancy_category =  Not for use in women
| legal_status = Unscheduled
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 398507-55-6
| DrugBank =
| PubChem = 4742795
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 3929995

<!--Chemical data-->
| C=23 | H=32 | N=6 | O=5 | S=1
| molecular_weight  = 504.602 g/mol
| smiles = CCCc1c2c(c(=O)nc([nH]2)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)CCO)n(n1)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C23H32N6O5S/c1-4-6-18-20-21(27(3)26-18)23(31)25-22(24-20)17-15-16(7-8-19(17)34-5-2)35(32,33)29-11-9-28(10-12-29)13-14-30/h7-8,15,30H,4-6,9-14H2,1-3H3,(H,24,25,31)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = NEYKRKVLEWKOBI-UHFFFAOYSA-N
}}

[[File:Lodenafil carbonate.svg|thumb|261px|right|Lodenafil carbonate]]

'''Lodenafil''' (also known as '''hydroxyhomosildenafil''', trade name '''Helleva''') is a drug belonging to a class of drugs called [[PDE5 inhibitor]], which many other erectile dysfunction drugs such as [[sildenafil]], [[tadalafil]], and [[vardenafil]] also belong to. Like [[udenafil]] and [[avanafil]] it belongs to a new generation of PDE5 inhibitors.

Lodenafil is formulated as a [[prodrug]] in the form of the [[carbonate ester]] [[Dimer (chemistry)|dimer]], '''lodenafil carbonate''', which breaks down in the body to form two molecules of the active drug lodenafil. This formulation has higher oral [[bioavailability]] than the parent drug.<ref name="pmid18593576">{{cite journal |vauthors=Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G |title=Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum |journal=European Journal of Pharmacology |volume=591 |issue=1–3 |pages=189–95 |date=September 2008 |pmid=18593576 |doi=10.1016/j.ejphar.2008.06.055 |url=}}</ref>

It is manufactured by [[Cristália Produtos Químicos e Farmacêuticos]] in [[Brazil]] and sold there under the brand-name Helleva.<ref>[http://www.2cristalia.com.br/lerNoticia.php?idN=776  Cristália] Product page. Retrieved on September 16, 2009.</ref>

It has undergone Phase III clinical trials,<ref name="pmid19040623">{{cite journal |vauthors=Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF, Pagani E |title=Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial |journal=The Journal of Sexual Medicine |volume=6 |issue=2 |pages=553–7 |date=February 2009 |pmid=19040623 |doi=10.1111/j.1743-6109.2008.01079.x |url=}}</ref><ref name="pmid20214718">{{cite journal |vauthors=Glina S, Fonseca GN, Bertero EB, Damião R, Rocha LC, Jardim CR, Cairoli CE, Teloken C, Torres LO, Faria GE, da Silva MB, Pagani E |title=Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial |journal=The Journal of Sexual Medicine |volume= 7|issue= 5|pages= 1928–1936|date=February 2010 |pmid=20214718 |doi=10.1111/j.1743-6109.2010.01711.x |url=}}</ref> but is not yet approved for use in the [[United States]] by the [[U.S. Food and Drug Administration]].

== See also ==
* [[Homosildenafil]]

== References ==
{{Reflist}}

{{Sexual dysfunction pharmacotherapies}}
{{Phosphodiesterase inhibitors}}
{{Piperazines}}

[[Category:PDE5 inhibitors]]

{{genito-urinary-drug-stub}}